Ann Surg Oncol

1. XU T, Xie X, Gu X, Zhang A, et al
   Combined RAS and SMAD4 Mutations and Microsatellite Instability Predict Outcomes in Colorectal Lung Metastases Treated with Image-Guided Thermal Ablation.
   Ann Surg Oncol. 2026;33:6274-6285.
   

   >> Share

   
   
2. SWAMINATHAN N, Xie R, Swaminathan S, Donahue JM, et al
   Surgery Versus Radiation for Stage 1A NSCLC in Nonagenarians: 20 Years of Data, Decisions, and Outcomes.
   Ann Surg Oncol. 2026;33:6252-6262.
   

   >> Share

   
   
3. DELGADO LM, da Nobrega Oliveira REN, Machado GF, Guerra LS, et al
   Cytoreductive Surgery With or Without HITHOC for Pleural Mesothelioma: A Meta-analysis of Survival and Perioperative Outcomes.
   Ann Surg Oncol. 2026;33:6306-6314.
   

   >> Share

   
   

   
   Ann Thorac Surg

4. TAJE R, Gallina FT, Spicer JD
   STAGE II NON-SMALL CELL LUNG CANCER: UPFRONT SURGERY OR NEOADJUVANT CHEMOIMMUNOTHERAPY.
   Ann Thorac Surg. 2026 Jun 9:S0003-4975(26)00536.
   

   >> Share

   
   

   
   Arch Bronconeumol

5. CALL S, Botana-Rial M, Cordovilla R, Galvez C, et al
   SEPAR-SECT Recommendations for Perioperative Invasive Mediastinal Staging of Non-small Cell Lung Cancer.
   Arch Bronconeumol. 2026 Jun 11:S0300-2896(26)00145.
   

   >> Share

   
   

   
   BMC Cancer

6. ZHAO N, Wu X, Zhao W, Cheng X, et al
   Characteristics and hematological indicators predictors of immunotherapy response in advanced non-small cell lung cancer.
   BMC Cancer. 2026 Jun 11. doi: 10.1186/s12885-026-16302.
   

   >> Share

   
   
7. LIN YJ, He MY, Xie Y, Yin ZY, et al
   Evaluation of cerebrospinal fluid human epididymis protein 4 for leptomeningeal metastasis in non-small cell lung cancer: a prospective cohort study.
   BMC Cancer. 2026 Jun 11. doi: 10.1186/s12885-026-16325.
   

   >> Share

   
   
8. XU Z, Li W, Yu Y, Wu H, et al
   Screening and identification of biomarkers in tumor-educated platelets for non-small cell lung cancer.
   BMC Cancer. 2026 Jun 8. doi: 10.1186/s12885-026-16307.
   

   >> Share

   
   

   
   Cancer Cell

9. SUN H, Zhao S, Li J, Zhang L, et al
   Targeting internalization, resistance, and response: Insights from ICARUS-LUNG01.
   Cancer Cell. 2026;44:1113-1115.
   

   >> Share

   
   

   
   Cancer Epidemiol Biomarkers Prev

10. GOLDWASSER DL
    How Wide is the Screening Window for Aggressive Non-Small Cell Lung Cancers? The Cure Threshold Metric and its Implications for Lung Cancer Screening Guidelines.
    Cancer Epidemiol Biomarkers Prev. 2026.
    

    >> Share

    
    

    
    Cancer Lett

11. LI KC, Gan S, Lu S, Yuan TK, et al
    USP48 stabilizes YBX1 to enforce a Wnt-driven stemness circuit and osimertinib resistance in EGFR-mutant NSCLC.
    Cancer Lett. 2026;654:218587.
    

    >> Share

    
    

    
    Cancer Sci

12. SHAO M, Yao J, Zhao L, Zhu L, et al
    Final Analysis of Neoadjuvant Sintilimab Plus Chemotherapy in IB-IIIA Non-Small-Cell Lung Cancer: Phase 2 neoSCORE Trial.
    Cancer Sci. 2026 Jun 7. doi: 10.1111/cas.70442.
    

    >> Share

    
    

    
    Carcinogenesis

13. FREEMAN B, Bian T, Xu G, Wheeler M, et al
    Assessing the physiological relevance of the bioactivation of tobacco-specific carcinogen NNK and its metabolite NNAL: quantitative analyses of hydrolysis products from their protein adducts under different carcinogen exposure conditions.
    Carcinogenesis. 2026;47:bgag031.
    

    >> Share

    
    

    
    Chest

14. FONSECA GA, Triplette M
    Lung Cancer Screening Guidelines: Moving Beyond Pack-Years for Equity and Efficiency.
    Chest. 2026;169:1457-1458.
    

    >> Share

    
    
15. OST DE
    Invasive Mediastinal Staging in Stage I Non-Small Cell Lung Cancer Treated With Radiation: Insights, Variation, and the Confounding Shadow of Stage Migration.
    Chest. 2026;169:1454-1456.
    

    >> Share

    
    
16. BROCK JM, van der Heijden EHFM, Herth FJF
    Robotic Bronchoscopy and Lung Cancer Stage Shift: Hype or Hope?
    Chest. 2026;169:1462-1463.
    

    >> Share

    
    

    
    Clin Cancer Res

17. RUGE L, John F, Verheyen M, Riedel R, et al
    Molecular and clinical characteristics of patients with non-small cell lung cancer (NSCLC) harboring KRAS Q61 mutations to assess therapeutic responses.
    Clin Cancer Res. 2026 Jun 10. doi: 10.1158/1078-0432.CCR-26-0133.
    

    >> Share

    
    

    
    Clin Exp Metastasis

18. AKPALAMUT D
    NF1 mutation may be associated with lung-tropic metastasis in cutaneous melanoma: a genomic analysis of 520 patients.
    Clin Exp Metastasis. 2026;43:32.
    

    >> Share

    
    
19. SPARTZ A, Schmidt S, Mohamed F, Troness B, et al
    Modeling the role of urokinase-type plasminogen activator, uPA, and circulating cancer-associated fibroblasts (cCAFs) in breast cancer cell extravasation.
    Clin Exp Metastasis. 2026;43:30.
    

    >> Share

    
    

    
    Clin Nucl Med

20. KIM DW, Park SA, Kim MH
    18 F-PSMA-1007 and 18 F-FDG PET/CT Findings of Pulmonary Tuberculosis Mimicking Malignancy.
    Clin Nucl Med. 2025 Sep 26. doi: 10.1097/RLU.0000000000006137.
    

    >> Share

    
    

    
    Hum Pathol

21. ALFAYEZ A, Belanger E, Cheung S, Churg A, et al
    TSC2, cathepsin K, and beta-catenin as immunohistochemical markers for lymphangioleiomyomatosis.
    Hum Pathol. 2026;174:106142.
    

    >> Share

    
    

    
    Int J Cancer

22. MOISEENKO F, Stroyakovskiy D, Levchenko E, Fedyanin M, et al
    Surgical Removal of Residual Tumor Masses in Patients Undergoing Targeted Therapy for EGFR-Mutated Locally Advanced or Metastatic Lung Cancer.
    Int J Cancer. 2026 Jun 11. doi: 10.1002/ijc.70543.
    

    >> Share

    
    

    
    J Immunol

23. REISCH K, Scherer A, Bartell R, Santana F, et al
    CD7 drives CD8 T cell exhaustion during chronic viral infection.
    J Immunol. 2026;215:vkag091.
    

    >> Share

    
    

    
    J Thorac Oncol

24. STONE E, Hu X, Afriyie-Mensah JS, Lee P, et al
    Advances in Diagnosis-Pulmonology.
    J Thorac Oncol. 2026;21:103648.
    

    >> Share

    
    
25. SINGH AK
    Blood-Based Biomarkers as Adjuncts to Computed Tomography Screening for Lung Cancer: Is the Rubber Ready for the Road?
    J Thorac Oncol. 2026;21:103694.
    

    >> Share

    
    
26. FAN Y, Zhao Y, Huang D, Zhao J, et al
    First-Line Tislelizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Extensive-Stage SCLC: A Long-Term Survival and Programmed Death-Ligand 1 Subgroup Analysis From the Randomized, Phase 3 RATIONALE-312 Trial.
    J Thorac Oncol. 2026;21:103655.
    

    >> Share

    
    
27. FENG J, Khan S, Waddell TK, Yasufuku K, et al
    Identifying Patients With High-Risk Stage I NSCLC Using a Tumor-Informed Plasma ctDNA Assay.
    J Thorac Oncol. 2026;21:103645.
    

    >> Share

    
    
28. NILSSON MB, Le X, Poteete A, Yu X, et al
    Loss of Payload Sensitivity and Other Mechanisms of Resistance to T-DXd in HER2-Mutant NSCLC: Implications for Subsequent Responsiveness to HER2 TKIs.
    J Thorac Oncol. 2026;21:103555.
    

    >> Share

    
    

    
    Lung Cancer

29. LEE EH, Kim MH, Kang DH, Moon J, et al
    Clinical impact of local consolidative therapy in EGFR-mutant metastatic NSCLC: A propensity-matched multicenter analysis.
    Lung Cancer. 2026;217:109423.
    

    >> Share

    
    
30. YOKOYAMA H, Serada S, Yamashita M, Suzuki Y, et al
    Glypican-1-targeted antibody-drug conjugate shows therapeutic efficacy in lung squamous cell carcinoma.
    Lung Cancer. 2026;217:109431.
    

    >> Share

    
    
31. WENG H, Li Y, Yang L, Chen S, et al
    Integrating chest CT-derived skeletal muscle index with SARC-F for sarcopenia screening in patients with lung cancer.
    Lung Cancer. 2026;218:109475.
    

    >> Share

    
    
32. UEHARA Y, Ikegami M, Kohsaka S, Kimura H, et al
    Real-world clinical characteristics and outcomes in patients with HER2-mutant non-small cell lung cancer (NSCLC) who received second-line treatment: A nationwide database analysis in Japan.
    Lung Cancer. 2026;218:109491.
    

    >> Share

    
    
33. LULA LJ, Costa R, Huang L, Rushwan A, et al
    European experience on oncological outcomes of patients with early-stage non-small cell lung cancer and any prior cancer following lobectomy or segmentectomy.
    Lung Cancer. 2026;217:109410.
    

    >> Share

    
    
34. KIM S, Kim IH, Kim JY, Yun JK, et al
    Refining N1 classification: prognostic validation of N1 subdivision in resected non-small cell lung cancer.
    Lung Cancer. 2026;218:109474.
    

    >> Share

    
    

    
    Nat Med

35. KIM YW, Park EJ, Kwak KI, Yoon TH, et al
    Electronic cigarette use after smoking cessation and lung cancer risk.
    Nat Med. 2026 Jun 8. doi: 10.1038/s41591-026-04469.
    

    >> Share

    
    

    
    Oncol Rep

36. ZHOU Y, Li R, Chen X, Zhang C, et al
    A fibroblast activation protein degrader enhances cisplatin sensitivity in non?small cell lung cancer.
    Oncol Rep. 2026;56:145.
    

    >> Share

    
    

    
    PLoS One

37. OZEN A, Harmankaya I, Ozdemir C, Halici M, et al
    Treatment terminations during radiation therapy: A retrospective descriptive single-center analysis.
    PLoS One. 2026;21:e0350496.
    

    >> Share

    
    
38. AL-DAMOOK N, Sakkal M, Khair M, Mousa WK, et al
    Mapping metabolic reprogramming in lung and breast cancer through integrative bioinformatics.
    PLoS One. 2026;21:e0350628.
    

    >> Share

    
    
39. ALGHAMDI B, Rocha S
    Exploring hypoxia-related genes as prognostic indicators in lung adenocarcinoma.
    PLoS One. 2026;21:e0349820.
    

    >> Share

    
    

    
    Proc Natl Acad Sci U S A

40. YUAN J, Ma Y, Dong Y, Zhang Z, et al
    Targeting XIAP-coordinated PKC signaling resensitizes PD-1-refractory tumors for rechallenge.
    Proc Natl Acad Sci U S A. 2026;123:e2600501123.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share